Compilation of Somatic Mutations of the CDKN2 Gene in Human Cancers: Non-Random Distribution of Base Substitutions

Genes Chromosomes and Cancer

Volumn 15, Issue 2, 1996, Pages 77-88

  Pollock, Pamela M ^a   Pearson, John V ^a   Hayward, Nicholas K ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN;

CARCINOGENESIS; CHROMOSOME 9P; CHROMOSOME MAP; GENE MUTATION; GENETIC LINKAGE; MELANOMA; NUCLEIC ACID BASE SUBSTITUTION; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CHROMOSOMES, HUMAN, PAIR 9; CODON; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DATABASES, FACTUAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MELANOMA; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; RNA SPLICING; SEQUENCE DELETION; TUMOR CELLS, CULTURED;

EID: 0030025518     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0     Document Type: Review

References (69)

1. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Pointen J (1991) A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88:10124-10128.
2. Brenner AJ, Aldaz CM (1995) Chromosome 9p allelic loss and p16/ CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res 55:2892-2895.
3. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D (1994) Rates of p16 (MTS1) mutations in primary tumours with 9p loss. Science 265: 415-416.
4. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8:27-32.
5. Cannon-Albright L, Goldgar D, Meyer L, Lewis C, Anderson D, Fountain J, Hegi M, Wiseman R, Petty E, Bale A, Olopade O, Diaz M, Kwiatkowski D, Piepkorn M, Zone J, Skolnick M (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258:1148-1152.
6. Cariello NF, Beroud C, Soussi T (1994) Database and software for the analysis of mutations at the human p53 gene. Nucleic Acids Res 22:3549-3550.
7. Caron de Fromental C, Soussi T (1992) TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosom Cancer 4:1-15.
8. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee W-C, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR (1994) p16 alterations and deletion mapping of 9p21-22 in malignant mesothelioma. Cancer Res 54:5547-5551.
9. Diaz MO, Rubin CM, Harden A, Ziemin S, Larson RA, Le Beau MM, Rowley JD (1990) Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med 322:77-82.
10. Eisenstadt E, Warren AJ, Porter J, Aitkens D, Miller JH (1982) Carcinogenic epoxides of benzo[a]pyrene and cyclopental-[cd]pyrene induce base substitutions via specific transversions. Proc Natl Acad Sci USA 79:1945-1949.
11. INK4 gene and surrounding chromosome 9p21 regions in sporadic melanoma. Cancer Res (submitted).
12. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlok DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J, Kidd VJ, Housman DE, Dracopoli NC (1992) Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 89:10557-10661.
13. Giani C, Finocchiaro G (1994) Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 54:6338-6339.
14. Goldstein A, Dracopoli N, Engelstein M, Fraser M, Clark WH Jr, Tucker M (1994) Linkage of cutaneous malignant melanoma/ dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet 54:489-496.
15. Gruis N, Sandkuijl L, Weber J, van der Zee A, Borgstein A-M, Bergman W, Frants R (1993) Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families, Effect of naevus count. Melanoma Res 3:271-277.
16. Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, Ponce-Castaneda V, Lianes P, Latres E, Skolnick M, Cordon-Cardo C, Kamb A (1995) Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 146:1199-1206.
17. Harris CC (1993) p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 262:1980-1981.
18. Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M, Nakamura Y (1994) Somatic mutations of the MTS (Multiple Tumor Suppressor) 1/CDK4I (cyclin dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 202:1426-1430.
19. Holland EA, Beaton SC, Edwards BG, Kefford RF, Mann GJ (1994) Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma. Oncogene 9:1361-1365.
20. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53.
21. Hollstein M, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorenson B, Montesano R, Harris CC (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551-3555.
22. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark Jr. WH, Tucker MA, Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nature Genet 8:15-21.
23. Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, Harada Y, Sugimura T, Terada M (1995) Mutation frequency of the p16/CDKN2 gene in primary cancers of the upper digestive tract. Cancer Res 55:3421-3423.
24. Isshiki K, Seng BA, Elder DE, Guerry D, Linnenbach AJ (1994) Chromosome 9 deletion in sporadic and familial melanomas in vivo. Oncogene 9:1649-1653.
25. Kai M, Arakawa H, Sugimoto Y, Murata Y, Ogawa M, Nakamura Y (1995) Infrequent somatic mutations of the MTS1 gene in primary bladder carcinomas. Jpn J Cancer Res 86:249-251.
26. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
27. Koh J, Enders GH, Dynlacht BD, Harlow E (1995) Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506-510.
28. Komiya A, Suzuki H, Aida S, Yatani R, Shimazaki J (1995) Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 86:622-625.
29. Kress S, Sutler C, Strickland PT, Mkhtar H, Schweizer J, Schwarz M (1992) Carcinogen-specific mutational pattern in the p53 gene in ultraviolet B radiation-induced squamous cell carcinomas of mouse skin. Cancer Res 52:6400-6403.
30. Li Y-J, Hoang-Xuan K, Delattre J-Y, Poisson M, Thomas G, Hamelin R (1995) Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 11:597-600.
31. INK4A mutation and protein disfunction in a family with inherited melanoma. Oncogene 11:405-412.
32. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A (1995b) CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10:1061-1067.
33. Lo K-W, Huang DP, Lau K-M (1995) p16 gene alterations in nasopharyngeal carcinoma. Cancer Res 55:2039-2043.
34. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J (1995) Retinoblastoma-protein-dependent cell cycle inhibition by the tumour suppressor p16. Nature 375:503-506.
35. Mori T, Miura K, Nishihira T, Mori S, Nakamura Y (1994) Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinomas. Cancer Res 54:3396-3397.
36. Moulton T, Samara G, Chung W-Y, Yuan L, Desai R, Sisti M, Bruce J, Tycko B (1995) MTS1/p16/CDKN2 lesions in primary glioblastomas multiforme. Am J Pathol 146:613-619.
37. Nancarrow D, Mann G, Holland K, Walker G, Beaton S, Walters M, Luxford C, Palmer J, Donald J, Weber J, Fountain J, Kefford R, Hayward N (1993) Confirmation of chromosome 9p linkage to melanoma. Am J Hum Genet 53:936-942.
38. Nobori T, Miura K, Wu DJ, Louis A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
39. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM, Huebner K (1994) Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 54: 5269-5272.
40. INK4 in human cancer. Proc Natl Acad Sci USA 91:11045-11049.
41. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55:1448-1451.
42. Olopade OI, Bohlander SK, Pomykala H, Maltepe E, Van Melle E, Le Beau MM, Diaz MO (1992a) Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics 14:437-443.
43. Olopade OI, Jenkins RB, Ranson DT, Malik K, Pomykala H, Nobori T, Cowan JM, Rowley JD, Diaz MO (1992b) Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res 52:2523-2529.
44. Olopade OI, Buchhagen DL, Malik K, Sherman J, Nobori T, Bader S, Nau MM, Gazdar AF, Minna JD, Diaz MO (1993) Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 53:2410-2415.
45. INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 55:1436-1440.
46. Packenham JP, Taylor JA, White CM, Anna CH, Barrett JC, Devereux TR (1995) Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. Clin Cancer Res 1:687-690.
47. Peiffer SL, Bartsch D, Whelan AJ, Mutch DG, Herzog TJ, Goodfellow PJ (1995) Low frequency of CDKN2 mutations in endometrial carcinomas. Mol Carcinogen 13:210-212.
48. Pollock PM, Yu F, Qiu L, Parsons PG, Hayward NK (1995) Evidence for UV induction of CDKN2 mutations in melanoma cell lines. Oncogene 11:663-668.
49. Quesnel B, Preudhomme C, Philippe N, Vanrumbeke M, Dervite I, Luc Lai J, Bauters F, Wattel E, Fenaux P (1995a) p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 85:657-663.
50. Quesnel B, Fenaux P, Philippe N, Fournier J, Bonneterre J, Preudhomme C, Peyrat JP (1995b) Analysis of p16 deletion and point mutation in breast carcinoma. Br J Cancer 72:351-353.
51. INK4 function. Nature Genet 10:114-116.
52. Reymond A, Brent R (1995) p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene 11:1173-1178.
53. Schmidt EE, Ichimura K, Reifenberger G, Collins VP (1994) CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54:6321-6324.
54. Schultz DC, Vanderveer L, Buetow KH, Boente VIP, Ozols RF, Hamilton TC, Godwin AK (1995) Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 55:2150-2157.
55. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
56. Sherr CJ (1993) Mammalian G1 cyclins. Cell 73:1059-1065.
57. Spruck CH III, Gonzalez-Zuleta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA (1994) p16 gene in uncultured tumours. Nature 370:183-184.
58. Sun Y, Hildesheim A, Lanier AEP, Cao Y, Yao K-T, Raab-Traub N, Yang C-S (1995) No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas. Oncogene 10:785-788.
59. Ueki K, Rubio M-P, Ramesh V, Correa KM, Rutter JI, von Deimling A, Buckler AJ, Gusella JF, Louis DN (1994) MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 3:1841-1845.
60. Walker GJ, Palmer JM, Walters MK, Nancarrow DJ, Parsons PG, Hayward NK (1994) Refined localisation of the melanoma (MLM) gene on chromosome 9p by analysis of allelic deletions. Oncogene 9:819-824.
61. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T, Takahashi T (1995) In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 55:514-517.
62. Xiao S, Li D, Corson JM, Vijg J, Fletcher JA (1995) Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res 55:2968-2971.
63. ink4) in human breast carcinomas. Cancer Res 54:5262-5264.
64. INK4 tumor suppressor protein. Cancer Res 55: 2503-2506.
65. Yeudall WA, Crawford RY, Ensley JF, Robbins KC (1994) MTS1/ CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinomas. Carcinogen 15:2683-2686.
66. Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 55: 2756-2760.
67. Zhang S-Y, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL (1994) Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050-5053.
68. Zhou X, Tarmin L, Yin J, Jiang H-Y, Suzuki H, Rhyu M-G, Abraham JM, Meltzer SJ (1994) The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9:3737-3741.
69. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE, Brash DE (1993) Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 90:4216-4220.